Leave no one behind: A global survey of the current state of geriatric oncology practice by SIOG national representatives.

Barriers Geriatric oncology National representatives Proposed actions SIOG

Journal

Journal of geriatric oncology
ISSN: 1879-4076
Titre abrégé: J Geriatr Oncol
Pays: Netherlands
ID NLM: 101534770

Informations de publication

Date de publication:
03 Feb 2024
Historique:
received: 02 10 2023
revised: 06 12 2023
accepted: 22 01 2024
medline: 4 2 2024
pubmed: 4 2 2024
entrez: 4 2 2024
Statut: aheadofprint

Résumé

The Sustainable Development Goals of the United Nations include a commitment to "leave no one behind" as a universal goal. To achieve this in geriatric oncology (GO) worldwide, it is important to understand the current state of GO at an international level. The International Society of Geriatric Oncology (SIOG) has several National Representatives (NRs) who act as SIOG's delegates in their respective countries. The NRs took part in this international survey exploring the state of GO practice, identifying barriers and solutions. The NRs answered open-ended questions by email from February 2020 to October 2022. The questionnaire domains included the demographic information of older adults for their countries, and the NRs' opinions on whether GO is developing, what the barriers are to developing GO, and proposed actions to remove these barriers. The demographic data of each country reported in the survey was adjusted using literature and database searches. Twenty-one of thirty countries with NRs (70%) participated in this questionnaire study: 12 European, four Asian, two North American, two South American, and one Oceanian. The proportion of the population aged ≥75 years varied from 2.2% to 15.8%, and the average life expectancy also varied from 70 years to 86 years. All NRs reported that GO was developing in their country; four NRs (18%) reported that GO was well developed. Although all NRs agreed that geriatric assessment was useful, only three reported that it was used day-to-day in their countries' clinical practice (14%). The major barriers identified were the lack of (i) evidence to support GO use, (ii) awareness and interest in GO, and (iii) resources (time, manpower, and funding). The major proposed actions were to (i) provide new evidence through clinical trials specific for GO patients, (ii) stimulate awareness through networking, and (iii) deliver educational materials and information to healthcare providers and medical students. This current survey has identified the barriers to GO and proposed actions that could remove them. Broader awareness seems to be essential to implementing GO. Additional actions are needed to develop GO within countries and can be supported through international partnerships.

Identifiants

pubmed: 38310661
pii: S1879-4068(24)00007-9
doi: 10.1016/j.jgo.2024.101709
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101709

Informations de copyright

Copyright © 2024 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest All the contributing authors declare no conflicts of interest.

Auteurs

Tomonori Mizutani (T)

Kyorin University Faculty of Medicine, Department of Medical Oncology, Tokyo, Japan. Electronic address: tomomizu@ks.kyorin-u.ac.jp.

Kwok-Leung Cheung (KL)

School of Medicine, University of Nottingham, Nottingham, United Kingdom.

Yervand Hakobyan (Y)

Hematology Center after Prof. Yeolyan, Hematology and Transfusion Medicine department of NIH Armenia, Yerevan, Armenia.

Heather Lane (H)

Sir Charles Gairdner Hospital, Geriatric and Rehabilitation Medicine Department, Perth, Australia.

Lore Decoster (L)

UZ Brussel, Vrije Universiteit Brussel, Department of Medical Oncology, Brussels, Belgium.

Theodora Karnakis (T)

The Cancer Institute of the State of São Paulo/University, Division of Geriatric Medicine, São Paulo, Brazil.

Martine Puts (M)

University of Toronto, Lawrence S. Bloomberg Faculty of Nursing, Toronto, Canada.

Oscar Calderon (O)

Clínica Alemana de Santiago and Complejo Asistencial Dr. Sótero del Río, Department of Geriatric Medicine, Santiago, Chile.

Trine L Jørgensen (TL)

Odense University Hospital, Department of Oncology, Odense, Denmark.

Rabia Boulahssass (R)

University Hospital of Nice, Geriatric Department, Nice, France.

Ulrich Wedding (U)

University Hospital Jena, Department of Palliative Care, Jena, Germany.

Athanasios Karampeazis (A)

The NIMTS Veterans Hospital, Medical Oncology Unit, Athens, Greece.

Wendy Wing Lok Chan (WWL)

Department of Clinical Oncology, The University of Hong Kong, China.

Joyita Banerjee (J)

All India Institute of Medical Sciences, Department of Geriatric Medicine, New Delhi, India.

Cristina Falci (C)

Medical Oncology 2, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.

Barbara L van Leeuwen (BL)

University medical center Groningen, Department of Surgery, Groningen, the Netherlands.

Vasco Fonseca (V)

Centro Hospitalar de Lisboa Ocidental, Department of Oncology, Lisboa, Portugal.

Regina Gironés Sarrió (R)

Hospital Universitari i Politècnic La FE, Department of Medical Oncology, Valencia, Spain.

Marcus Vetter (M)

Affiliation Cancer Center Baselland, Kantonsspital Baselland, Liestal, Switzerland.

Vérène Dougoud (V)

The HFR Hospital, Department of Medical Oncology, Fribourg, Switzerland.

Arash Naeim (A)

UCLA and Samueli School of Engineering and Applied Science, Departments of Medicine and Bioengineering, Calfornia, United States.

Jed Ashman (J)

Sandwell and West Birmingham NHS Trust, Birmingham City Hospital, Birmingham, United Kingdom; International Society of Geriatric Oncology, Geneva, Switzerland.

Najia Musolino (N)

International Society of Geriatric Oncology, Geneva, Switzerland.

Ravindran Kanesvaran (R)

National Cancer Centre Singapore, Department of Medical Oncology, Singapore, Singapore.

Classifications MeSH